PRESS RELEASE OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal hyperplasiaDesigned to resist competition from endogenous ACTH by maximizing receptor residency timeOMS1620 demonstrates best-in-class efficacy in acute and chronic preclinical models of ACTH excess Oxford, United Kingdom – 14th July 2025 – OMass Therapeutics (‘OMass’ or ‘the ...